Deutsche Bank AG Grows Position in Progyny, Inc. (NASDAQ:PGNY)

Deutsche Bank AG lifted its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 533.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 376,357 shares of the company's stock after purchasing an additional 316,918 shares during the period. Deutsche Bank AG owned 0.44% of Progyny worth $6,492,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Voya Investment Management LLC raised its position in Progyny by 1.4% during the 4th quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock valued at $893,000 after purchasing an additional 701 shares during the last quarter. Signaturefd LLC increased its stake in shares of Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after buying an additional 1,355 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after acquiring an additional 1,526 shares in the last quarter. KBC Group NV lifted its stake in Progyny by 84.6% in the fourth quarter. KBC Group NV now owns 4,669 shares of the company's stock worth $81,000 after acquiring an additional 2,140 shares during the period. Finally, F M Investments LLC lifted its stake in Progyny by 13.0% in the fourth quarter. F M Investments LLC now owns 20,420 shares of the company's stock worth $352,000 after acquiring an additional 2,342 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a research report on Monday, March 31st. Bank of America boosted their price target on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. JPMorgan Chase & Co. raised their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Finally, Canaccord Genuity Group cut their price objective on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $23.45.

Progyny Stock Down 1.2%

Shares of NASDAQ PGNY traded down $0.26 on Friday, reaching $20.64. 115,588 shares of the company's stock traded hands, compared to its average volume of 1,707,172. The business's 50 day simple moving average is $22.17 and its two-hundred day simple moving average is $19.90. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $30.42. The company has a market cap of $1.77 billion, a price-to-earnings ratio of 35.59, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). The firm had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business's revenue for the quarter was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.17 EPS. Analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.